Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AAV1-gSG

Next Previous
Drug Profile

AAV1-gSG

Alternative Names: AAV1-gamma-sarcoglycan gene therapy - Genethon; AAV1-gamma-sarcoglycan vector injection - Genethon; Adeno-associated viral 1 vector-mediated gamma-sarcoglycan gene therapy - Genethon; Adeno-associated viral vector containing the human gamma-sarcoglycan gene - Genethon; Adeno-associated virus 1-gamma-sarcoglycan gene therapy - Genethon; Gamma sarcoglycanopathy gene therapy - Genethon

Latest Information Update: 23 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViroMed Co Ltd
  • Developer Genethon
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoglycanopathies
  • New Molecular Entity No

Highest Development Phases

  • No development reported Sarcoglycanopathies

Most Recent Events

  • 23 Feb 2023 Discontinued - Preclinical for Sarcoglycanopathies in France (IV)
  • 23 Feb 2023 Discontinued - Preclinical for Sarcoglycanopathies in USA (IM)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Sarcoglycanopathies in France (IM, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top